European stocks were broadly higher Tuesday afternoon with investors indulging in some buying in resources, defense and banking sectors ahead of the upcoming New Year holidays. Trading volumes remained thin, but the major kept edging higher gradually after a steady start.The pan European Stoxx 600 climbed 0.56%. The U.K.'s FTSE 100 gained 0.5%, Germany's DAX advanced 0.57% and France's CAC 40 moved up 0.56%. Switzerland's SMI advanced 0.18%.In the German market, Rheinmetall moved up 2.5%. Infineon climbed ...

The major U.S. index futures are currently pointing to a lower open on Monday, with stocks likely to give back ground after turning in a strong performance last week.Profit taking may contribute to initial weakness on Wall Street, as some traders look to cash in on recent gains going into the end of the year.Partly reflecting renewed strength among tech stocks, the Dow and the S&P 500 ended last Thursday's trading at record closing highs before edging slightly lower last Friday.A pullback by big-name tech ...

Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi’s tolebrutinib for nrSPMS shows need for safe therapy BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the submission of its seventh annual Development Safety Update Report (DSUR) to the U.S. Food an ...

Asian shares were mixed Thursday in thin holiday trading, with most markets in the region and elsewhere closed for Christmas.In Tokyo, the Nikkei 225 edged 0.1 per cent higher to 50,407.79. It has gained nearly 30 per cent this year.The dollar slipped to 155.85 Japanese yen from 155.94 yen. The euro climbed to US$1.1786 from US$1.1780.Markets in mainland China advanced, with the Shanghai Composite index up 0.5 per cent at 3,959.62. Hong Kong’s exchange was closed.Investors were encouraged by a statement by ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 13 Best Debt Free Dividend Stocks to Buy Now. Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN) On December 12, Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $768 from $767 and kept an Equal Weight rating. The firm expects many of the policy concerns that weighed on biopharma this year to fade in 2026. As those pressures ease, attention is likely to sh ...

March S&P 500 E-Mini futures (ESH26) are trending down -0.03% this morning as trading resumed after the Christmas holiday, with activity subdued and volumes expected to remain light ahead of a shortened New Year’s week. Higher bond yields today are weighing on S&P 500 futures. The 10-year T-note yield rose two basis points to 4.15%. More News from Barchart In Wednesday’s trading session, Wall Street’s three main equity benchmarks closed higher, with the S&P 500 posting a new record high. Nike (NKE) cl ...

Group 1 - Nvidia Corp. shares increased to $190.16 in overnight trading after announcing a non-exclusive licensing agreement with AI chip startup Groq, which covers its inference technology [1][1][1] - Dynavax Technologies Corp. shares surged 38.2% to close at $15.38 following Sanofi's announcement to acquire the vaccines company [1][1][1] - Sobr Safe Inc. shares jumped 82.3% to close at $2.37 after announcing definitive agreements to issue 1.29 million shares of common stock at $1.55 per share in a private placement [1][1][1] Group 2 - Davis Commodities Ltd. reported revenue of $95 million for the six months ending June 30, a 42.1% increase from $66.9 million a year earlier, but shares fell 8.9% to close at $0.24 [1][1][1] - Biohaven Ltd. disclosed that its Phase 2 proof-of-concept study of BHV-7000 in major depressive disorder did not meet its primary endpoint, with shares gaining 3% to close at $10.81 [1][1][1]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

Core Viewpoint - Dynavax Technologies Corp. is set to be acquired by Sanofi for $2.2 billion, leading to a significant increase in its stock price by 38.19% to $15.38 on the announcement day [1][5]. Group 1: Acquisition Details - Dynavax has officially entered into an agreement with Sanofi to acquire all outstanding shares at a price of $15.50 each, representing a premium of approximately 39% over its closing price on December 23 [2]. - The acquisition will enhance Sanofi's presence in adult immunization, particularly through Dynavax's adult hepatitis B vaccine, Heplisav-B, which offers a two-dose regimen that provides faster seroprotection compared to traditional three-dose vaccines [3]. Group 2: Vaccine Portfolio and Development - The acquisition includes Dynavax's shingles vaccine candidate (Z-1018), currently in phase 1/2 clinical development, along with other vaccine pipeline projects [4]. - Dynavax's CEO emphasized that joining Sanofi will leverage global scale and expertise to maximize the impact of their vaccine portfolio, addressing significant public health needs [5].

U.S. financial markets are observing a full closure today, Thursday, December 25, 2025, in celebration of the Christmas holiday. Trading on both the New York Stock Exchange (NYSE) and Nasdaq is suspended for the entire day, with normal operations set to resume on Friday, December 26, 2025. This pause follows a shortened, yet record-setting, trading session on Christmas Eve, Wednesday, December 24, where major indexes continued their upward trajectory, fueling hopes of a "Santa Claus rally" to close out the ...